Heyman Tomas J.
- SEC CIK
- 0001814673
No open-market purchases or sales filed in the past year.
Current role at each company
- LEGN Legend Biotech CorpDirectoras of Sep 28, 2026
- EXEL Exelixis, Inc.Directoras of May 29, 2026
- AKRO Akero Therapeutics, Inc.Directoras of Dec 9, 2025
- OPTN OptiNose, Inc.Directoras of May 21, 2025
- XLO Xilio Therapeutics, Inc.Directoras of Jun 13, 2023
Show 1 more company
- IVVD Invivyd, Inc.Directoras of May 25, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Heyman Tomas J. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
EXEL Exelixis, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2025 (view filing) | May 21 | 1 day | Heyman Tomas J.Director | SSale | −4.54K | $44.29 | −$201.3K | −12.3%32.5K after |
AKRO Akero Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 21, 2023 (view filing) | Jun 16 | 5 days | Heyman Tomas J.Director | SSale | −26.0K | $54.67 | −$1.42M | −100.0%0 after |